New diabetes drug underway from Diamyd

The Swedish biotechnology group Diamyd have claimed that its leading diabetes drug candidate is efficient.
The group were testing the drugs efficacy in preserving insulin production in a phase II human clinical trial. The drug, which is also called Diamyd, was tested on 70 children and adolescents who have type 1 diabetes.
According to the company the results were very positive: ” serious adverse events associated with the therapy were observed. The Principal Investigator found that the treatment is easy to give and that the study outcomes are of clinical importance for the treatment of type 1-diabetes.”
The chief executive of Diamyd, Anders Essen-Moller, said that the company would now: “evaluate and execute its strategies on how to bring Diamyd to the market. This may include taking Diamyd to the market ourselves, aggressively seeking high-value international pharmaceutical partnerships for the co-development of Diamyd, or a mixture of both.”
Diamyd the drug is designed to reduce the need to administer insulin injections and decrease the destruction of beta cells.